ストックスクリーナーアプリを入手
5.16
3.73%
-0.20
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Weekly Recap: FDA acceptance, June 29 date and Brokers keep Buy ratings - TradingView
Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCYUnicycive Therapeutics Inc Short Interest - Finviz
Bragar Eagel & Squire, P.C. is Investigating Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. Files Form 8-K for Key Event on July 2, 2026 – Company Details, NASDAQ Ticker, and Emerging Growth Status – Minichart - Minichart
Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026 - TradingView
Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ FDA reject on the previous reject. See below. - Moomoo
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Carroll County Mirror-Democrat
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Yahoo Finance
Form 144 Unicycive Therapeutics For: 1 July By Investing.com - Investing.com Canada
Unicycive Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Unicycive plummets following second CRL for OLC for hyperphosphatemia - MSN
UNCY Maintained by Benchmark -- Price Target Lowered to $13.00 - GuruFocus
UNCY Maintained by Noble Capital Markets -- Price Target Lowered to $50 - GuruFocus
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for - GlobeNewswire
Benchmark cuts Unicycive Therapeutics price target on FDA setback - Investing.com UK
Why Is Unicycive Therapeutics Stock Falling Tuesday? - Sahm
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY) - Seeking Alpha
Benchmark cuts Unicycive Therapeutics price target on FDA setback By Investing.com - Investing.com South Africa
Powerful - Moomoo
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $37 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Unicycive Therapeutics stock tumbles on FDA rejection letter - Investing.com
Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA - mydailyrecord.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Unicycive shares plunge after FDA issues complete response letter for kidney disease drug (UNCY) - MSN
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
UNCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Law firm probes Unicycive Therapeutics after FDA rejects drug application, stock falls - Pluang
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors - GlobeNewswire
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors - GlobeNewswire Inc.
Unicycive receives FDA rejection for kidney disease drug - Investing.com UK
$Unicycive Therapeutics (UNCY.US)$ - Moomoo
B. Riley Securities Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Why is Unicycive Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Unicycive gets FDA CRL for OLC kidney drug application - grafa.com
UNCY Extends ATM Offering As Dilution Fears Hit The Chart - StocksToTrade
US FDA declines to approve Unicycive's kidney disease drug - Reuters
US Stocks Mixed; Home Prices Increase 1.1% In April - Benzinga
Unicycive slides as FDA delay, dilution weigh premarket - TechStock²
FDA rejects drug again for same manufacturing issue, chopping stock in half - The Business Journals
UNCY Stock Slides As $150M Shelf Fuels Dilution Fears - timothysykes.com
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) - Yahoo Finance
Unicycive Therapeutics stock tumbles on FDA rejection letter By Investing.com - Investing.com Nigeria
US FDA declines to approve Unicycive's drug for dialysis patients - marketscreener.com
Unicycive’s kidney drug hits FDA setback as label talks continue - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ It is Good News. - Moomoo
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Index - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2500 Growth Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Value Benchmark Index - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Value Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Unicycive Therapeutics stock reiterated at Buy by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Growth Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell 3000E Growth Benchmark - marketscreener.com
Unicycive Therapeutics' Framework For Speedier Clinical Trials - Clinical Leader
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell Microcap Index - marketscreener.com
1.53%
3.59%
大文字化:
|
ボリューム (24 時間):